Business acquisition - Narrative (Details) - USD ($) $ in Thousands		1 Months Ended				3 Months Ended	10 Months Ended
	Dec. 01, 2021	Jan. 31, 2023	Dec. 31, 2022	Jan. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Sep. 30, 2022
Abveris
Business Acquisition [Line Items]
Fair value of consideration transferred	$ 102,645
Cash	$ 9,467
Equity (in shares)	759,601
Company common stock	$ 72,514
Options consideration	6,400
Contingent consideration	8,500
Holdback Liabilities	12,800
Net working capital adjustment	$ 674
Contingent consideration, shares issuable up to (in shares)	334,939
Indemnity holdbacks period	18 months
Indemnity holdback shares (in shares)	128,351
Indemnity holdback options (in shares)	15,304
Holdback before adjustment	$ 12,500
Adjustment holdback shares (in shares)	3,416		166			166
Adjustment holdback options (in shares)	408
Value of adjustment holdback	$ 300
Post combination compensation expenses includes employee stock awards					$ 41,000
Vesting period	2 years
Gain related to change in fair value during the period						$ 3,721	$ 13,471
Abveris | Awards with vesting requirements
Business Acquisition [Line Items]
Post combination compensation expenses includes employee stock awards					$ 17,700
Vesting period					2 years
Abveris | Awards without vesting requirements
Business Acquisition [Line Items]
Post combination compensation expenses includes employee stock awards					$ 3,200
Abveris | Performance Shares
Business Acquisition [Line Items]
Post combination compensation expenses includes employee stock awards					$ 20,100
iGenomX
Business Acquisition [Line Items]
Company common stock	$ 66,100			$ 4,600
Contingent consideration (in shares)			171,551		59,190
iGenomX | Subsequent events
Business Acquisition [Line Items]
Company common stock		$ 4,100